Epidiolex maker GW Pharma reports record quarterly revenue of $137 million
United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales…
News November 4
Latest In: GW Pharmaceuticals
GW Pharmaceuticals cannabis drug gets regulatory OK in Australia
GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in…
News September 24
Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact
United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges…
News August 7
FDA approves GW Pharmaceuticals’ cannabis drug for new indication
CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a…
News August 3
UK down-schedules Epidyolex to lowest level for controlled drugs
The United Kingdom has down-scheduled Epidyolex to the lowest level of control for drugs, greatly easing restrictions on…
News June 24
GW Pharma trims loss to $8 million, warns virus could hit sales
GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but…
News May 12
New Zealand eases prescription requirement for cannabis-based medicine Sativex
Doctors in New Zealand no longer require Ministry of Health approval to prescribe Sativex, according to a new…
News April 9
DEA removes cannabis drug Epidiolex from controlled substances list
Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered…
News April 7
GW Pharma beats projections with $108M in Q4 sales thanks to CBD drug
A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana.
News January 13Featured
1
Latest Sponsored
